{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:46:54Z","timestamp":1791391614572,"version":"4.3.3"},"reference-count":209,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Neuromyelitis optica spectrum disorders (NMOSDs) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) are autoimmune inflammatory disorders of the central nervous system (CNS). Pain is highly prevalent and debilitating in NMOSD and MOGAD with a severe impact on quality of life, and there is a critical need for further studies to successfully treat and manage pain in these rare disorders. In NMOSD, pain has a prevalence of over 80%, and pain syndromes include neuropathic, nociceptive, and mixed pain, which can emerge in acute relapse or become chronic during the disease course. The impact of pain in MOGAD has only recently received increased attention, with an estimated prevalence of over 70%. These patients typically experience not only severe headache, retrobulbar pain, and\/or pain on eye movement in optic neuritis but also neuropathic and nociceptive pain. Given the high relevance of pain in MOGAD and NMOSD, this article provides a systematic review of the current literature pertaining to pain in both disorders, focusing on the etiology of their respective pain syndromes and their pathophysiological background. Acknowledging the challenge and complexity of diagnosing pain, we also provide a mechanism-based classification of NMOSD- and MOGAD-related pain syndromes and summarize current treatment strategies.<\/jats:p>","DOI":"10.3389\/fneur.2020.00778","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T07:44:44Z","timestamp":1609746284000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":85,"title":["Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies"],"prefix":"10.3389","volume":"11","author":[{"given":"Susanna","family":"Asseyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"116396","DOI":"10.1016\/j.jns.2019.07.014","article-title":"Devic's index case: a critical reappraisal \u2013 AQP4-IgG-mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis?","volume":"407","author":"Jarius","year":"2019","journal-title":"J Neurol Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2055217318796684","article-title":"Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"4","author":"Asseyer","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrneurol.2014.129","article-title":"Pain in neuromyelitis optica - prevalence, pathogenesis and therapy","volume":"10","author":"Bradl","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B4","volume-title":"De la neuromy\u00e9lite optique aigu\u00eb","author":"Gault","year":"1894"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-012-0320-5","article-title":"Pain and multiple sclerosis: pathophysiology and treatment","volume":"13","author":"Solaro","year":"2012","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1097\/j.pain.0000000000000492","article-title":"Neuropathic pain: an updated grading system for research and clinical practice","volume":"157","author":"Finnerup","year":"2016","journal-title":"Pain."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(99)03313-9","article-title":"Acute pain","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/j.pain.0000000000000160","article-title":"A classification of chronic pain for ICD-11","volume":"156","author":"Aziz","year":"2015","journal-title":"Pain."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1212\/NXI.0000000000000583","article-title":"Collaborative international research in clinical and longitudinal experience study in NMOSD","volume":"6","author":"Cook","year":"2019","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1371\/journal.pmed.0040133","article-title":"Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica","volume":"4","author":"Paul","year":"2007","journal-title":"PLoS Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/bpa.12087","article-title":"Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status","volume":"23","author":"Sato","year":"2013","journal-title":"Brain Pathol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: A multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation."},{"key":"B18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/WNL.0b013e318229e694","article-title":"Pain in neuromyelitis optica and its effect on quality of life a cross-sctional study","volume":"77","author":"Kanamori","year":"2011","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1212\/NXI.0000000000000286","article-title":"Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder","volume":"3","author":"Chavarro","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3389\/fneur.2019.00608","article-title":"Cognitive impairment in neuromyelitis optica spectrum disorders: a review of clinical and neuroradiological features","volume":"10","author":"Oertel","year":"2019","journal-title":"Front Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1212\/NXI.0000000000000094","article-title":"Sleep abnormality in neuromyelitis optica spectrum disorder","volume":"2","author":"Song","year":"2015","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nrneurol.2017.117","article-title":"Fatigue as a symptom or comorbidity of neurological diseases","volume":"13","author":"Penner","year":"2017","journal-title":"Nat Publ Gr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"102027","DOI":"10.1016\/j.msard.2020.102027","article-title":"Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: results of an international survey","volume":"41","author":"D'Souza","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.msard.2017.07.014","article-title":"Patient perspectives on neuromyelitis optica spectrum disorders: data from the patients like me online community","volume":"17","author":"Eaneff","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1177\/1352458514522103","article-title":"Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life","volume":"20","author":"Zhao","year":"2014","journal-title":"Mult Scler."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1001\/archneurol.2012.768","article-title":"Association of neuromyelitis optica with severe and intractable pain","volume":"69","author":"Qian","year":"2012","journal-title":"Arch Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e71500","DOI":"10.1371\/journal.pone.0071500","article-title":"The major brain endocannabinoid 2-AG controls neuropathic pain and mechanical hyperalgesia in patients with neuromyelitis optica","volume":"8","author":"Pellkofer","year":"2013","journal-title":"PLoS ONE."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1001\/archneurol.2012.112","article-title":"Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics","volume":"69","author":"Kim","year":"2012","journal-title":"Arch Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.nrleng.2014.12.015","article-title":"Neuromyelitis optica: association with paroxysmal painful tonic spasms","volume":"31","author":"Carnero Contentti","year":"2015","journal-title":"Neurologia."},{"key":"B31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/archneurol.2011.832","article-title":"Association between paroxysmal tonic spasms and neuromyelitis optica","volume":"69","author":"Usmani","year":"2012","journal-title":"Arch Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.msard.2017.07.004","article-title":"Painful tonic spasm in neuromyelitis optica spectrum disorders: prevalence, clinical implications and treatment options","volume":"17","author":"Liu","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease : a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"key":"B34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis : international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflam."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1212\/NXI.0000000000000131","article-title":"Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis","volume":"2","author":"Chalmoukou","year":"2015","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s00415-017-8615-8","article-title":"Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France","volume":"264","author":"Biotti","year":"2017","journal-title":"J Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults","volume":"90","author":"Papeix","year":"2018","journal-title":"Neurology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1212\/NXI.0000000000000543","article-title":"Cranial nerve involvement in patients with MOG antibody-associated disease","volume":"6","author":"Cobo-Calvo","year":"2019","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1212\/NXI.0000000000000619","article-title":"Expanding the MOG phenotype: brainstem encephalitis with punctate and curvilinear enhancement","volume":"6","author":"Matesanz","year":"2019","journal-title":"Neurol Neuroimmunol neuroinflamm."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1212\/NXI.0000000000000538","article-title":"Anti-MOG encephalitis mimicking small vessel CNS vasculitis","volume":"6","author":"Patterson","year":"2019","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders : a multicenter study of 50 patients. Part 3 : Brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS : a clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0000000000000681","article-title":"Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults","volume":"32","author":"Cobo-Calvo","year":"2019","journal-title":"Curr Opin Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3988\/jcn.2020.16.1.124","article-title":"Comparison of neuropathic pain in neuromyelitis optica and multiple sclerosis","volume":"16","author":"Hyun","year":"2020","journal-title":"Korean Neurol Assoc."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3109\/09638288.2013.833301","article-title":"Life on hold: the experience of living with neuromyelitis optica","volume":"36","author":"Mutch","year":"2014","journal-title":"Disabil Rehabil."},{"key":"B51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2016.06.041","article-title":"Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status","volume":"368","author":"Kong","year":"2016","journal-title":"J Neurol Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/1352458512457720","article-title":"Neuropathic pruritus (itch) in neuromyelitis optica","volume":"19","author":"Elsone","year":"2012","journal-title":"Mult Scler J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/jnnp-2016-314991","article-title":"Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis","volume":"88","author":"Tackley","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B54","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.msard.2020.101965","article-title":"Prodromal headache in MOG-antibody positive optic neuritis","volume":"40","author":"Asseyer","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1900","DOI":"10.1212\/WNL.0000000000009370","article-title":"Scrambler therapy improves pain in neuromyelitis optica","volume":"94","author":"Mealy","year":"2020","journal-title":"Neurology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"101432","DOI":"10.1016\/j.msard.2019.101432","article-title":"Subcortical structural abnormalities in female neuromyelitis optica patients with neuropathic pain","volume":"37","author":"Wang","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B57","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.pmn.2019.03.003","article-title":"Review of treatment for central spinal neuropathic pain and its effect on quality of life : implications for neuromyelitis optica spectrum disorder","volume":"20","author":"Mealy","year":"2019","journal-title":"Pain Manag Nurs."},{"key":"B58","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3344\/kjp.2014.27.1.77","article-title":"A case of neuromyelitis optica misdiagnosed as cervicogenic headache","volume":"27","author":"Choi","year":"2014","journal-title":"Korean J Pain."},{"key":"B59","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod Rheumatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1750-3639.2009.00365.x","article-title":"A 10-year old girl with neck pain","volume":"20","author":"Horbinski","year":"2010","journal-title":"Brain Pathol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s11606-008-0767-x","article-title":"Pelvic pain as an unusual first presentation of a demyelinating disease","volume":"23","author":"Loschner","year":"2008","journal-title":"J Gen Intern Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.msard.2016.01.006","article-title":"Trigeminal autonomic cephalalgia as a presenting feature of neuromyelitis optica: \u201ca rare combination of two uncommon disorders","volume":"6","author":"Mathew","year":"2016"},{"key":"B63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.msard.2018.07.032","article-title":"Flaccid paralysis in neuromyelitis optica: an atypical presentation with possible involvement of the peripheral nervous system","volume":"25","author":"Gr\u00fcter","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B64","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/1352458519840747","article-title":"Relapsing lumbosacral myeloradiculitis: an unusual presentation of MOG antibody disease","volume":"26","author":"Sundaram","year":"2019","journal-title":"Mult Scler J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pjnns.2015.10.010","article-title":"Painful tonic spasms and brainstem involvement in a patient with neuromyelitis optica spectrum disorder","volume":"50","author":"Roman-Filip","year":"2016","journal-title":"Neurol Neurochir Pol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s13760-014-0418-4","article-title":"Intractable hiccup and vomiting, neuropathic pruritus and tonic spasms in a case of neuromyelitis optica spectrum disorder","volume":"115","author":"El Otmani","year":"2015","journal-title":"Acta Neurol Belg."},{"key":"B67","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.msard.2015.07.011","article-title":"Successful treatment of paroxysmal tonic spasms with topiramate in a patient with neuromyelitis optica","volume":"4","author":"Iida","year":"2015","journal-title":"Mult Scler Relat Disord."},{"key":"B68","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3109\/01658107.2013.856027","article-title":"Horner syndrome in a case of neuromyelitis optica","volume":"38","author":"Lovera","year":"2014","journal-title":"Neuro Ophthalmol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica - IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1212\/NXI.0000000000000134","article-title":"Update on biomarkers in neuromyelitis optica","volume":"2","author":"Melamed","year":"2015","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B72","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1146\/annurev.neuro.29.051605.112929","article-title":"Neutrophins: mediators and modulators of pain","volume":"29","author":"Pezet","year":"2006","journal-title":"Annu Rev Neurosci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/ejn.12466","article-title":"Pro-neurotrophins, sortilin, and nociception","volume":"39","author":"Lewin","year":"2014","journal-title":"Eur J Neurosci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11916-017-0620-1","article-title":"Headache in neuromyelitis optica","volume":"21","author":"Masters-Israilov","year":"2017","journal-title":"Curr Pain Headache Rep."},{"key":"B75","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/SPC.0000000000000211","article-title":"Autoantibodies and pain","volume":"10","author":"Dawes","year":"2016","journal-title":"Curr Opin."},{"key":"B76","first-page":"279087","volume-title":"Associations Between Neuropathic Pain and Thalamic Ventral Posterior Nucleus Volume In Neuromyelitis Optica Spectrum Disorders","author":"Asseyer","year":"2019"},{"key":"B77","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1212\/WNL.0000000000005619","article-title":"Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder","volume":"90","author":"Hacohen","year":"2018","journal-title":"Neurology."},{"key":"B78","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B79","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ncpneuro0764","article-title":"Mechanisms of disease: Aquaporin-4 antibodies in neuromyelitis optica","volume":"4","author":"Jarius","year":"2008","journal-title":"Nat Clin Pract Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1083\/jcb.201504106","article-title":"The myelin oligodendrocyte glycoprotein directly binds nerve growth factor to modulate central axon circuitry","volume":"210","author":"von","year":"2015","journal-title":"J Cell Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1177\/1352458518815596","article-title":"Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity","volume":"25","author":"Chien","year":"2018","journal-title":"Mult Scler J."},{"key":"B84","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1352458515591069","article-title":"Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging","volume":"22","author":"Pekcevik","year":"2016","journal-title":"Mult Scler J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/bpa.12386","article-title":"Early and extensive spinal white matter involvement in neuromyelitis optica","volume":"27","author":"Hayashida","year":"2017","journal-title":"Brain Pathol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1007\/s00330-009-1425-3","article-title":"Spinal cord lesions in patients with neuromyelitis optica : a retrospective long-term MRI follow-up study","volume":"19","author":"Krampla","year":"2009","journal-title":"Eur Soc Radiol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00415-008-0545-z","article-title":"Preferential spinal central gray matter involvement in neuromyelitis optica: An MRI study","volume":"255","author":"Nakamura","year":"2008","journal-title":"J Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jneuroim.2012.09.010","article-title":"Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid","volume":"254","author":"Asgari","year":"2013","journal-title":"J Neuroimmunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2377-13-33","article-title":"Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study","volume":"13","author":"Asgari","year":"2013","journal-title":"BMC Neurol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1111\/j.1526-4610.2009.01427.x","article-title":"Frequency of chronic headaches in japanese patients with multiple sclerosis: with special reference to opticospinal and common forms of multiple sclerosis","volume":"49","author":"Doi","year":"2009","journal-title":"Headache."},{"key":"B91","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S1474-4422(09)70133-4","article-title":"Pathophysiology of trigeminal autonomic cephalalgias","volume":"8","author":"Leone","year":"2009","journal-title":"Lancet Neurol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/sj.bjp.0702247","article-title":"Release of immunoreactive substance P in the brain stem upon stimulation of the cranial dura mater with low pH - inhibition by the serotonin (5-HT1) recetpr agonist CP 93,129","volume":"125","author":"Messlinger","year":"1998","journal-title":"Br J Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00415-014-7298-7","article-title":"Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions","volume":"261","author":"Wang","year":"2014","journal-title":"J Neurol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-017-0123-5","article-title":"Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy","volume":"9","author":"Oertel","year":"2018","journal-title":"EPMA J."},{"key":"B95","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamaneurol.2017.3890","article-title":"Association of visual impairment in neuromyelitis optica spectrum disorder with visual network reorganization","volume":"75","author":"Finke","year":"2018","journal-title":"JAMA Neurol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult Scler J."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1212\/NXI.0000000000000334","article-title":"Microstructural visual system changes in AQP4-antibody-seropositive NMOSD","volume":"4","author":"Oertel","year":"2017","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B98","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/WCO.0000000000000551","article-title":"Mechanisms for lesion localization in neuromyelitis optica spectrum disorders","volume":"31","author":"Bradl","year":"2018","journal-title":"Curr Opin Neurol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1001\/jamaneurol.2013.3124","article-title":"Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica","volume":"70","author":"Matiello","year":"2013","journal-title":"JAMA Neurol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-5-22","article-title":"Neuromyelitis optica pathogenesis and aquaporin 4","volume":"5","author":"Graber","year":"2008","journal-title":"J Neuroinflamm."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1212\/NXI.0000000000000347","article-title":"Foveal thinning in neuromyelitis optica a sign of retinal astrocytopathy?","volume":"4","author":"Yamamura","year":"2017","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms6472","article-title":"Oligodendrocyte ablation triggers central pain independently of innate or adaptive immune responses in mice","volume":"5","author":"Gritsch","year":"2014","journal-title":"Nat Commun."},{"key":"B103","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11916-010-0143-5","article-title":"Tension-type headache and migraine in multiple sclerosis","volume":"14","author":"Kister","year":"2010","journal-title":"Curr Pain Headache Rep."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11910-017-0803-5","article-title":"Physiopathology of migraine: what have we learned from functional imaging?","volume":"17","author":"Russo","year":"2017","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B105","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/(SICI)1098-1136(199609)18:1<39::AID-GLIA4>3.0.CO;2-Z","article-title":"Myelid\/Oligodendrocyte glycoprotein (MOG) Expression is associated with myelin deposition","volume":"18","author":"Solly","year":"1996","journal-title":"Glia."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","author":"Vincent","year":"2018","journal-title":"Cephalgia."},{"key":"B107","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10072-018-3334-1","article-title":"Pain in optic neuropathies","volume":"39","author":"Marzoli","year":"2018","journal-title":"Neurol Sci."},{"key":"B108","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/0333102417703761","article-title":"Facial pain : overlapping syndromes","volume":"37","author":"Evers","year":"2017","journal-title":"Cephalgia."},{"key":"B109","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10072-015-2167-4","article-title":"Headaches attributed to visual disturbances","volume":"36","author":"Marzoli","year":"2015","journal-title":"Neurol Sci."},{"key":"B110","first-page":"145","article-title":"Controversies in optic neuritis pain diagnosis","volume":"6","author":"Agostini","year":"1987","journal-title":"J Mec Theor Appl."},{"key":"B111","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.autrev.2018.01.001","article-title":"Autoimmunity reviews diagnosis and management of neuromyelitis optica spectrum disorders - an update","volume":"17","author":"Bruscolini","year":"2018","journal-title":"Autoimmun Rev."},{"key":"B112","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1212\/NXI.0000000000000135","article-title":"Acute optic neuritis: unmet clinical needs and model for new therapies","volume":"2","author":"Galetta","year":"2015","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B113","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrneurol.2014.108","article-title":"The investigation of acute optic neuritis: a review and proposed protocol","volume":"10","author":"Petzold","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1212\/NXI.0000000000000270","article-title":"Optic neuropathy associated with systemic sarcoidosis","volume":"3","author":"Kidd","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1177\/1352458517734070","article-title":"A population-based prospective study of optic neuritis","volume":"23","author":"Soelberg","year":"2017","journal-title":"Mult Scler."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","article-title":"Epidemiologic and clinical characteristics of optic neuritis in Japan","volume":"126","author":"Ishikawa","year":"2019","journal-title":"Ophthalmology."},{"key":"B118","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody\u2013positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"e007766","DOI":"10.1136\/bmjopen-2015-007766","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis","volume":"5","author":"Nakajima","year":"2015","journal-title":"BMJ Open."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci7100138","article-title":"Pattern recognition of the multiple sclerosis syndrome","volume":"7","author":"Zabad","year":"2017","journal-title":"Brain Sci."},{"key":"B121","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.msard.2017.09.023","article-title":"Cerebral cortical encephalitis followed by recurrent NS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies","volume":"18","author":"Zhou","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B122","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000494092","article-title":"Headache at the time of first symptom manifestation of multiple sclerosis: a prospective, longitudinal study","volume":"80","author":"Gebhardt","year":"2018","journal-title":"EurNeurol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/1352458512459785","article-title":"Meningoencephalitis as an initial manifestation of neuromyelitis optica spectrum disorder","volume":"19","author":"Wang","year":"2012","journal-title":"Mult Scler J."},{"key":"B124","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/ene.12566","article-title":"Current symptomatology in multiple sclerosis and neuromyelitis optica","volume":"22","author":"Muto","year":"2015","journal-title":"Eur J Neurol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology."},{"key":"B126","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.msard.2016.11.009","article-title":"NMOSD triggered by yellow fever vaccination \u2013 an unusual clinical presentation with segmental painful erythema","volume":"11","author":"Sch\u00f6berl","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B127","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/head.13126","article-title":"Acute-onset severe occipital neuralgia associated with high cervical lesion in patients with neuromyelitis optica spectrum disorder","volume":"57","author":"Hayashi","year":"2017","journal-title":"Headache."},{"key":"B129","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jns.2015.06.004","article-title":"Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis","volume":"355","author":"Sugiyama","year":"2015","journal-title":"J Neurol Sci."},{"key":"B130","first-page":"185","article-title":"Paroxysmal pruritus as the first relapsing symptom of neuromyelitis optica","volume":"15","author":"Lee","year":"2010","journal-title":"Neurol Asia."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1212\/WNL.0b013e3182703ff7","article-title":"Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody","volume":"79","author":"Takai","year":"2012","journal-title":"Neurology."},{"key":"B133","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.clinph.2013.08.023","article-title":"Possible second motor neuron damage in neuromyelitis optica","volume":"125","author":"Laemmer","year":"2014","journal-title":"Clin Neurophysiol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"847670","DOI":"10.1155\/2013\/847670","article-title":"Abnormal nerve conduction study findings indicating the existence of peripheral neuropathy in multiple sclerosis and neuromyelitis optica","volume":"2013","author":"Warabi","year":"2013","journal-title":"Biomed Res Int."},{"key":"B135","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.msard.2017.09.006","article-title":"Radiculopathy in neuromyelitis optica. how does anti-AQP4 Ab involve PNS?","volume":"18","author":"Kim","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B136","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jocn.2015.12.048","article-title":"Etiological, clinical, and radiological features of longitudinally extensive myelopathy in Chinese patients","volume":"32","author":"Zhang","year":"2016","journal-title":"J Clin Neurosci."},{"key":"B137","first-page":"279523","volume-title":"Peripheral Nervous System Involvement in Mog Antibody-Associated Demyelination","author":"Ramanathan","year":"2019"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e503","DOI":"10.1212\/NXI.0000000000000503","article-title":"MOG antibodies in combined central and peripheral demyelination syndromes","volume":"5","author":"Do Campo","year":"2018","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B139","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0304-3940(03)00899-1","article-title":"Myelin oligodendrocyte glycoprotein is expressed in the peripheral nervous system of rodents and primates","volume":"350","author":"Pagany","year":"2003","journal-title":"Neurosci Lett."},{"key":"B140","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1586\/14737175.2013.865877","article-title":"Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice","volume":"13","author":"Pozzilli","year":"2013","journal-title":"Expert Rev Neurother."},{"key":"B141","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10072-015-2196-z","article-title":"Neuromyelitis optica spectrum disorders with multiple brainstem manifestations : a case report","volume":"37","author":"Li","year":"2016","journal-title":"Neurol Sci."},{"key":"B142","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s13760-014-0389-5","article-title":"Commentary on neuromyelitis optica associated with painful paroxysmal dystonia: case report and literature review","volume":"115","author":"Rodr\u00edguez-Quiroga","year":"2014","journal-title":"Acta Neurol Belg."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1177\/1352458512472748","article-title":"Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders","volume":"19","author":"Kim","year":"2013","journal-title":"Mult Scler J."},{"key":"B144","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.msard.2017.05.007","article-title":"Membranous nephropathy with Neuromyelitis optica spectrum disorder","volume":"15","author":"Li","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B145","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/mdc3.12321","article-title":"Spinal movement disorders in neuromyelitis optica: an under-recognized phenomenon","volume":"3","author":"Abboud","year":"2016","journal-title":"Mov Disord."},{"key":"B146","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pain.2007.08.024","article-title":"Pain associated with multiple sclerosis: systematic review and proposed classification","volume":"137","author":"O'Connor","year":"2008","journal-title":"Pain."},{"key":"B147","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ana.23909","article-title":"Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica","volume":"74","author":"Ciccarelli","year":"2013","journal-title":"Ann Neurol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2017","journal-title":"Ann N Y Acad Sci."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1177\/1352458511403958","article-title":"Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders","volume":"17","author":"Jarius","year":"2011","journal-title":"Mult Scler J."},{"key":"B150","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Mult Scler J."},{"key":"B152","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s13760-019-01176-6","article-title":"Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders","volume":"120","author":"Gkaniatsou","year":"2019","journal-title":"Acta Neurol Belg."},{"key":"B153","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5152\/eurjrheum.2018.18041","article-title":"Positive anti-MOG antibodies in a patient with sj\u00f6gren's syndrome and transverse myelitis","volume":"6","author":"Jobling","year":"2019","journal-title":"Eur J Rheumatol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.40356","article-title":"Understanding the antibody repertoire in neuropsychiatric systemic lupus erythematosus and neuromyelitis optica spectrum disorder: do they share common targets?","volume":"70","author":"Mader","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/rheumatology\/key282","article-title":"Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus","volume":"58","author":"Pr\u00f6bstel","year":"2019","journal-title":"Rheumatology."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/jnr.23844","article-title":"Pain in autoimmune disorders","volume":"95","author":"Mifflin","year":"2017","journal-title":"J Neurosci Res."},{"key":"B157","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00281-018-0723-8","article-title":"Sex differences in autoimmune disorders of the central nervous system","volume":"41","author":"Gold","year":"2019","journal-title":"Semin Immunopathol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/acn3.51008","article-title":"Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies","volume":"7","author":"Yeo","year":"2020","journal-title":"Ann Clin Transl Neurol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/00002508-199706000-00006","article-title":"Chronic pain-associated depression: antecedent or consequence of chronic pain?","volume":"13","author":"Fishbain","year":"1997","journal-title":"A Rev Clin J Pain."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1749259","article-title":"Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders","author":"Duchow","year":"2020","journal-title":"Expert Opin Biol Ther."},{"key":"B162","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.3389\/fimmu.2018.02066","article-title":"Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in south China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Immunol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B165","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/NXI.0000000000000510","article-title":"Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders","volume":"5","author":"Levy","year":"2018","journal-title":"Neurol Neuroimmunol NeuroInflamm."},{"key":"B166","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord."},{"key":"B169","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Terzi","year":"2019","journal-title":"New Engl J Med Orig."},{"key":"B170","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med."},{"key":"B172","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/13543784.2018.1443077","article-title":"Investigational drugs in development to prevent neuromyelitis optica relapses","volume":"27","author":"Paul","year":"2018","journal-title":"Expert Opin Investig Drugs."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet."},{"key":"B174","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-16625-7","article-title":"Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica","volume":"11","author":"Agasing","year":"2020","journal-title":"Nat Commun."},{"key":"B176","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0607-6","article-title":"Interleukin-6: an emerging regulator of pathological pain","volume":"13","author":"Zhou","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B177","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B178","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B179","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B181","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B182","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/pm\/pnz075","article-title":"A comprehensive algorithm for management of neuropathic pain","volume":"20","author":"Bates","year":"2019","journal-title":"Pain Med."},{"key":"B183","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neurol.2018.08.005","article-title":"Pharmacological treatments of neuropathic pain : the latest recommendations","volume":"175","author":"Attal","year":"2018","journal-title":"Rev Neurol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1055\/s-0038-1673679","article-title":"Neuropathic Pain","volume":"38","author":"Macone","year":"2018","journal-title":"Semin Neurol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1055\/s-0036-1584950","article-title":"Neuropathic Pain","volume":"36","author":"Gierthm\u00fchlen","year":"2016","journal-title":"Semin Neurol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pain.2010.07.031","article-title":"NeuPSIG guidelines on neuropathic pain assessment","volume":"152","author":"Haanp\u00e4\u00e4","year":"2011","journal-title":"Pain."},{"key":"B187","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.04.007","article-title":"Treatment of neuropathic pain: an overview of recent guidelines","volume":"122","author":"O'Connor","year":"2009","journal-title":"Am J Med."},{"key":"B188","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","article-title":"Recommendations for the pharmacological management of neuropathic pain: an overview and literature update","volume":"85","author":"Dworkin","year":"2010","journal-title":"Mayo Clin Proc."},{"key":"B190","first-page":"844","article-title":"Pharmacologic management of chronic neuropathic pain","volume":"63","author":"Mu","year":"2017","journal-title":"Can Fam Physician."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"Efns guidelines efns guidelines on the pharmacological treatment of neuropathic pain : 2010 revision","volume":"17","author":"Hansson","year":"2010","journal-title":"Eur J Neurol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18112483","article-title":"Analgesic mechanisms of antidepressants for neuropathic pain","volume":"18","author":"Obata","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B193","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1097\/j.pain.0000000000001522","article-title":"Translational neuropathic pain research","volume":"160","author":"Attal","year":"2019"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta7400","article-title":"Treatments for spasticity and pain in multiple sclerosis","volume":"7","author":"Beard","year":"2003","journal-title":"Health Technol Assess."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-0969-0","article-title":"Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options","volume":"20","author":"Stefano","year":"2019","journal-title":"J Headache Pain."},{"key":"B196","unstructured":"NICE Clin GuidelNeuropathic pain in adults : pharmacological management in non-specialist settings2013"},{"key":"B197","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1007\/s00520-016-3177-3","article-title":"Scrambler therapy for the management of chronic pain","volume":"24","author":"Majithia","year":"2016","journal-title":"Support Care Cancer."},{"key":"B198","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/ner.13119","article-title":"Invasive motor cortex stimulation influences intracerebral structures in patients with neuropathic pain: an activation likelihood estimation meta-analysis of imaging data","volume":"23","author":"Volkers","year":"2020","journal-title":"Neuromodulation"},{"key":"B199","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.clinph.2020.02.003","article-title":"Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014\u20132018)","volume":"131","author":"Lefaucheur","year":"2020","journal-title":"Clin Neurophysiol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/jnnp.2004.035972","article-title":"Clinical management of spasticity","volume":"76","author":"Thompson","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B201","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA Neurol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-018-0859-x","article-title":"Cannabinoids for treatment of ms symptoms : state of the evidence","volume":"18","author":"Rice","year":"2018","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B203","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1590\/S0004-282X2012005000011","article-title":"Paroxysmal dystonia and neuromyelitis optica","volume":"70","author":"Schmidt","year":"2011","journal-title":"Arq Neuropsiquiatr."},{"key":"B204","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1471-2377-11-104","article-title":"A modified score to identify and discriminate neuropathic pain: a study on the german version of the neuropathic pain symptom inventory (NPSI)","volume":"11","author":"Sommer","year":"2011","journal-title":"BMC Neurol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.pjnns.2014.07.009","article-title":"Symptomatology and pathogenesis of different types of pain in multiple sclerosis","volume":"48","author":"Brola","year":"2014","journal-title":"Neurol Neurochir Pol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD007963.pub3","article-title":"Oxcarbazepine for neuropathic pain","volume":"12","author":"Zhou","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"B207","first-page":"18","article-title":"New concepts of chronic pain and the potential role of complementary therapies","volume":"26","author":"Wojcikowski","year":"2018","journal-title":"Altern Ther Health Med."},{"key":"B208","unstructured":"Multidisciplinary treatment programs for patients with chronic non-malignant pain : a review of clinical effectiveness, cost- effectiveness, and guidelines\n            GauthierK\n            DulongC\n            Arg\u00e1ezC\n          31449369CADTH Rapid Response Rep.2017"},{"key":"B209","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/practneurol-2012-000237","article-title":"A practical guide to the treatment of neuromyelitis optica","volume":"12","author":"Palace","year":"2012","journal-title":"Pract Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.00778\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T07:45:02Z","timestamp":1609746302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.00778\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":209,"alternative-id":["10.3389\/fneur.2020.00778"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00778","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"article-number":"778"}}